High Court Turns Down Teva Unit's Provigil Patent Appeal

Law360, New York (December 16, 2013, 1:30 PM EST) -- The U.S. Supreme Court on Monday declined to take up an appeal by a unit of Teva Pharmaceutical Industries Ltd. of a Federal Circuit finding that its patent for the narcolepsy medicine Provigil is invalid and unenforceable.

As is customary, the high court declined Cephalon Inc.'s petition for a writ of certiorari without comment. Generic-drug maker Apotex Inc. brought the underlying suit in 2006, accusing the Israeli drugmaker of conspiring to keep generic versions of Provigil off the market. Apotex claimed a French company called Laboratoire Lafon...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.